Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?

التفاصيل البيبلوغرافية
العنوان:	Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?
المؤلفون:	Vitale P; Oncology Operative Unit, Hospital of Frattamaggiore, Frattamaggiore, Italy., De Falco V; Oncology Operative Unit, Hospital of Frattamaggiore, Frattamaggiore, Italy., Addeo R; Oncology Operative Unit, Hospital of Frattamaggiore, Frattamaggiore, Italy.
المصدر:	Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2024 Jul; Vol. 24 (7), pp. 481-484. Date of Electronic Publication: 2024 May 13.
نوع المنشور:	Editorial
اللغة:	English
بيانات الدورية:	Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE
أسماء مطبوعة:	Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: London : Future Drugs Ltd., c2001-
مواضيع طبية MeSH:	Cetuximab/administration & dosage , Cetuximab/pharmacology , Neoplasm Recurrence, Local/drug therapy , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/pathology , Antineoplastic Agents, Immunological/administration & dosage , Antineoplastic Agents, Immunological/pharmacology , Neoplasm Metastasis, Humans
فهرسة مساهمة:	Keywords: PD-L1; Recurrent/metastatic head and neck cancer; cetuximab; chemotherapy; combined positive score; pembrolizumab
المشرفين على المادة:	PQX0D8J21J (Cetuximab) 0 (Antineoplastic Agents, Immunological)
تواريخ الأحداث:	Date Created: 20240511 Date Completed: 20240620 Latest Revision: 20240620
رمز التحديث:	20240620
DOI:	10.1080/14737140.2024.2354772
PMID:	38733083
قاعدة البيانات:	MEDLINE

PDF full text from Publisher

الوصف
تدمد:	1744-8328
DOI:	10.1080/14737140.2024.2354772